Navigation Links
Updated Pictures of CEL-SCI Manufacturing Facility Available Online
Date:12/3/2008

VIENNA, Va., Dec. 3 /PRNewswire-FirstCall/ -- In response to numerous shareholder inquiries, CEL-SCI Corporation (NYSE Alternext US: CVM) announced today that it has added updated pictures of it new manufacturing facility to its website. The pictures can be accessed through CEL-SCI's homepage (http://www.cel-sci.com) by clicking on the link "Updated Pictures of Manufacturing Facility" in the special highlights section.

CEL-SCI is developing its cancer product Multikine(R) for approval as a first line indication in head and neck cancer. The manufacturing facility was built to supply the upcoming and FDA cleared Phase III clinical trial, as well as commercial sale, of Multikine as a first line indication in treatment naive head and neck cancer patients. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

CEL-SCI already has two partners who will participate in the Phase III trial: Teva Pharmaceuticals and Orient Europharma of Taiwan. Discussions with other potential partners are ongoing.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% of the patients and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed very promising results in animal tests.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. StollerUSA Launches Updated Web site For Growers and Farmers
2. Updated Online Tutorials for DBTSS, Pfam and PDB
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
6. Biopure Launches Updated Website
7. SleepQuest Launches Updated Web Site
8. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
9. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
10. CEL-SCI Takes Delivery of New Manufacturing Facility
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):